Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck

Oral Diseases

Volumn 15, Issue 2, 2009, Pages 121-132

  Ko, C ^a   Citrin, D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Head and neck cancer; Radiation treatment

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; ANTINEOPLASTIC AGENT; AQUAPORIN 1; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; PALIFERMIN; PENTOXIFYLLINE; PILOCARPINE;

ACUTE TOXICITY; ALOPECIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CHRONIC TOXICITY; CLINICAL TRIAL; DYSGEUSIA; DYSPHAGIA; EAR DISEASE; FIBROSIS; GASTROINTESTINAL TOXICITY; HEAD AND NECK CARCINOMA; HIGH RISK POPULATION; HOARSENESS; HUMAN; HYPERHIDROSIS; HYPOPHARYNX TUMOR; HYPOTHYROIDISM; INTENSITY MODULATED RADIATION THERAPY; LACRIMATION; LARYNX TUMOR; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; ODYNOPHAGIA; OROPHARYNX TUMOR; PAIN; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PROTECTION; REVIEW; RHINITIS; SEPSIS; SIDE EFFECT; SKIN ATROPHY; SKIN DISCOLORATION; SKIN FIBROSIS; SKIN NECROSIS; SOFT TISSUE INJURY; SQUAMOUS CELL CARCINOMA; SWEATING; TELANGIECTASIA; THERAPY EFFECT; TREATMENT PLANNING; URINARY FREQUENCY; WEIGHT REDUCTION; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS;

EID: 60349106861     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2008.01495.x     Document Type: Review

References (101)

1. Adelstein DJ, Tan EH, Lavertu P (1996). Treatment of head and neck cancer: the role of chemotherapy. Crit Rev Oncol Hematol 24 : 97 116.
2. Adelstein DJ, Li Y, Adams GL et al (2003). An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 : 92 98.
3. Al-Sarraf M, LeBlanc M, Giri PG et al (1998). Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 : 1310 1317.
4. Ang KK, Harris J, Garden AS et al (2005). Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol 23 : 3008 3015.
5. Baillet F (1997). Alpha-tocopherol treatment of radio-fibrosis post-brachytherapy for breast cancer. Radiother Oncol 43 : S3 (Abstract 9).
6. Baum BJ, Voutetakis A, Wang J (2004). Salivary glands: novel target sites for gene therapeutics. Trends Mol Med 10 : 585 590.
7. Ben-David MA, Diamante M, Radawski JD et al (2007). Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys 68 : 396 402.
8. Bentzen SM (2006). Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6 : 702 713.
9. Bernier J, Domenge C, Ozsahin M et al (2004). Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 : 1945 1952.
10. Bhandare N, Kennedy L, Malyapa RS et al (2007). Primary and central hypothyroidism after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 68 : 1131 1139.
11. Bonner JA, Maihle NJ, Folven BR et al (1994). The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 29 : 243 247.
12. Bonner JA, Harari PM, Giralt J et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 : 567 578.
13. Braaksma MM, Wijers OB, van Sornsen de Koste JR et al (2003). Optimisation of conformal radiation therapy by intensity modulation: cancer of the larynx and salivary gland function. Radiother Oncol 66 : 291 302.
14. Brizel DM (2008). Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 26 : 2489 2496.
15. Brizel DM, Wasserman T (2004). The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow-up of a prospective randomized trial (abstract). Proc Am Soc Clin Oncol 23 : 495.
16. Brizel DM, Albers ME, Fisher SR et al (1998). Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 : 1798 1804.
17. Brizel DM, Wasserman TH, Henke M et al (2000). Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 : 3339 3345.
18. Burlage FR, Roesink JM, Kampinga HH (2008). Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys 70 : 14 22.
19. Chao KS, Low D, Perez CA et al (2000). Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int J Cancer 90 : 92 103.
20. Claus F, Duthoy W, Boterberg T et al (2002). Intensity modulated radiation therapy for oropharyngeal and oral cavity tumors: clinical use and experience. Oral Oncol 38 : 597 604.
21. Cooper JS, Fu K, Marks J et al (1995). Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys 31 : 1141 1164.
22. Cooper JS, Pajak TF, Forastiere AA et al (2004). Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 : 1937 1944.
23. Daisne JF, Sibomana M, Bol A et al (2003). Evaluation of a multimodality image (CT, MRI, and PET) coregistration procedure on phantom and head and neck cancer patients: accuracy, reproducibility and consistency. Radiother Oncol 69 : 237 245.
24. Delanian S, Balla-Mekias S, Lefaix JL (1999). Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J Clin Oncol 17 : 3283 3290.
25. Delanian S, Porcher R, Balla-Mekias S et al (2003). Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 21 : 2545 2550.
26. Denis F, Garaud P, Bardet E et al (2004). Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22 : 69 76.
27. Dion M, Hussey D, Doornbos J et al (1990). Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int J Radiat Oncol Biol Phys 19 : 401 407.
28. Domenge C, Hill C, Lefebvre JL et al (2000). Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer 83 : 1594 1598.
29. Eisbruch A (2007). Commentary: induction chemotherapy for head and neck cancer: hypothesis-based rather than evidence-based medicine. Oncologist 12 : 975 977.
30. Eisbruch A, Kim HM, Terrell HE et al (2001). Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 : 695 704.
31. Eisbruch A, Schwartz M, Rasch C et al (2004). Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 60 : 1425 1439.
32. El-Sayed S, Nelson N (1996). Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 14 : 838 847.
33. Epstein JB, Robertson M, Emerton S et al (2001). Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 23 : 389 398.
34. Fan Z, Masui H, Altas I et al (1993). Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53 : 4322 4328.
35. Feng FY, Kim HM, Lyden TH et al (2007). Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68 : 1289 1298.
36. Forastiere AA, Goepfert H, Maor M et al (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 : 2091 2098.
37. Fu KK, Pajak TF, Trotti A et al (2000). A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 : 7 16.
38. Giles FJ, Miller CB, Hurd DD et al (2003). A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMT-T trial). Leuk Lymphoma 44 : 1165 1172.
39. Greene FL, Page DL, Fleming ID et al (2002). AJCC (American Joint Committee on Cancer) Manual for staging of cancer, 6th edn. Springer-Verlag : New York, pp. 17 67.
40. Grover EA, Christie AC, Merritt EA et al (1929). Roentgen radiation in the treatment of hyperthyroidism: a statistical evaluation based on 305 cases. JAMA : 1730 1734.
41. Gunderson LL, Tepper JE 2007. Head and neck tumors, clinical radiation oncology, 2nd edn. Elsevier : Philadelphia, pp. 629 852.
42. Hall EJ, Giaccia AJ 2006. Radioprotectors, radiosensitizers and bioreductive drugs, radiobiology for the radiologist, 6th edn. Lippincott Williams &Wilkins : Philadelphia, pp. 129 134, 419 431.
43. Harari PM (1997). Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J Clin Oncol 15 : 2050 2055.
44. Harrison LB, Zelefsky MJ, Pfister DG et al (1997). Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 19 : 169 175.
45. Hockel M, Vaupel P (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 : 266 276.
46. Horiot JC, Le Fur R, N'Guyen T et al (1992). Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25 : 231 241.
47. Horiot JC, Bontemps P, van den Bogaert W et al (1997). Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44 : 111 121.
48. Huang K, Xia P, Chuang C et al (2008). Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer 113 : 497 507.
49. Hughes PJ, Scott PM, Kew J et al (2000). Dysphagia in treated nasopharyngeal cancer. Head Neck 22 : 393 397.
50. Huguenin PU, Taussky D, Moe K et al (1999). Quality of life in patients cured from a carcinoma of the head and neck by radiotherapy: the importance of the target volume. Int J Radiat Oncol Biol Phys 45 : 47 52.
51. Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 : 341 354. [Erratum, Nat Rev Cancer 2005;5: 580.]
52. Jemal A, Siegel R, Ward E et al (2007). Cancer statistics, 2007. CA Cancer J Clin 67 : 43 66.
53. Jereczek-Fossa BA, Alterio D, Jassem J et al (2004). Radiotherapy induced thyroid disorders. Cancer Treat Rev 30 : 369 384.
54. Kies MS, Haraf DJ, Rosen F et al (2001). Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 19 : 1961 1969.
55. Kim JH, Chu FC, Lakshmi V et al (1986). Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx. Am J Clin Oncol 9 : 132 134.
56. Koh WJ, Rasey JS, Evans ML et al (1992). Imaging of hypoxis in human tumors with [F-18]Fluoromisonidazole. Int J Radiat Oncol Biol Phys 22 : 199 212.
57. Kuten A, Lubochitski R, Fishman G et al (1996). Postradiotherapy hypothyroidism: radiation dose response and chemotherapeutic radiosensitization at less than 40 Gy. J Surg Oncol 61 : 281 283.
58. Lee AWN, Ng SH, Ho JHC et al (1988). Clinical diagnosis of late temporal lobe necrosis following radiation therapy for nasopharyngeal carcinoma. Cancer 61 : 1535 1542.
59. Lefebvre JL, Chevalier D, Luboinski B et al (1996). Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88 : 890 899.
60. Leibel SA, Phillips T (2004). Textbook of radiation oncology, 2nd edn. Philadelphia : Saunders.
61. Levin W (2005). The use of pentoxifylline and vitamin E in the treatment of late radiation related injuries. Clin Trials. gov identifier: NCT00188552.
62. Liang K, Ang KK, Milas L et al (2003). The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57 : 246 254.
63. Littley MD, Shalet SM, Beardwell CG (1990). Radiation and hypothalamic-pituitary function. Baillieres Clin Endocrinol Metab 4 : 147 175.
64. Maciejewski B, Withers HR, Taylor JMG et al (1990). Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx. Part 2. Normal tissue response: acute and late effects. Int J Radiat Oncol Biol Phys 18 : 101 111.
65. Marcus RB, Million RR (1990). The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 19 : 3 8.
66. Mendelsohn J, Baselga J (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21 : 2787 2799.
67. Merlano M, Benasso M, Corvò R et al (1996). Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88 : 583 589.
68. Million RR, Cassisi NJ (1994). The effect of radiation on normal tissues of the head and neck, management of head and neck cancer a multidisciplinary approach, 2nd edn. J.B. Lippincott Company : Philadelphia, 245 290.
69. Mossman KL (1983). Quantitative radiation dose-response relationships for normal tissues in man: II. Response of the salivary glands during radiotherapy. Radiat Res 95 : 392 398.
70. Nutting C, Convery DJ, Cosgrove VP et al (2001). Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol 60 : 173 180.
71. Nuyts S, Dirix P, Clement PM et al (2008). Impact of Adding Concomitant Chemotherapy to Hyperfractionated Accelerated Radiotherapy for Advanced Head-and-Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2008 Aug 14. Epub ahead of print.
72. Okunieff P, Augustine E, Hicks JE et al (2004). Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol 22 : 2207 2213.
73. Pignon JP, Bourhis J, Domenge C et al (2000). Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355 : 949 955.
74. Pignon JP, le Maître A, Bourhis J MACH-NC Collaborative Group (2007). Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 69 (Suppl. 2 S112 S114.
75. Posner MR, Weichselbaum RR, Fitzgerald TJ et al (1985). Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 11 : 1887 1893.
76. Rajendran JG, Schwartz OL, O'Sullivano J et al (2006). Tumor hypoxia imaging with [F-18] Fluoromisonidazole position emission tomography in head and neck cancer. Clin Cancer Res 12 : 5435 5441.
77. Ramirez-Amador V, Silverman S Jr., Mayer P et al (1997). Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84 : 149 153.
78. Reuther T, Schuster T, Mende U et al (2003). Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients - a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 32 : 289 295.
79. Rosenthal DI, Lewin JS, Eisbruch A (2006). Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 24 : 2636 2643.
80. Saadeh CE (2005). Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment. Pharmacotherapy 25 : 540 554.
81. Saarilahti K, Kouri M, Collan J et al (2005). Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 74 : 251 258.
82. Sanguineti G, Sosa M, Culp L et al (2004). Is it feasible to spare part of the mucosa with IMRT and does it matter. Int J Radiat Oncol Biol Phys 60 : S517 S518.
83. Schubert MM, Sullivan KMJ, Truelove EL (1991). Head and neck complication of bone marrow transplantation. Dev Oncol 36 : 401 427.
84. Scully C, Epstein JB (1996). Oral health care for the cancer patient. Eur J Cancer B Oral Oncol 32B : 281 292.
85. Sonis ST (1997). Oral complications. In : Holland JF, Bast Jr. RC, Morton DL, eds Cancer medicine, 4th edn. Willams & Wilkins : Philadelphia, pp. 3255 3264.
86. Sonis ST (2004). The pathobiology of mucositis. Nat Rev Cancer 4 : 277 284.
87. Soo KC, Tan EH, Wee J et al (2005). Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer 93 : 279 286.
88. Spalding TA, Trotter C, Skjaerbaek N et al (2002). Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol 61 : 1297 1302.
89. The Department of Veteran's Affairs Laryngeal Cancer Study Group (1991). Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 : 1685 1690.
90. Titcomb CP (2001). High incidence of nasopharyngeal carcinoma in Asia. J Insur Med 33 : 235 238.
91. Trotti A, Bellm LA, Epstein JB et al (2003). Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66 : 253 262.
92. Trotti A, Garden A, Warde P et al (2004). A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 58 : 674 681.
93. Trotti A, Colevas AD, Setser A et al (2007). Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25 : 5121 5127.
94. Tupchong L, Scott CB, Blitzer PH et al (1991). Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 20 : 21 28.
95. Vissink A, Jansma J, Spijkervet FK et al (2003). Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14 : 199 212.
96. Vokes EE, Weichselbaum RR, Lippman SM et al (1993). Head and neck cancer. N Engl J Med 328 : 184 194.
97. Vokes EE, Stenson K, Rosen FR et al (2003). Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck caner. J Clin Oncol 21 : 320 326.
98. Wahl MJ (2006). Osteoradionecrosis prevention myths. Int J Radiat Oncol Biol Phys 64 : 661 669.
99. Weissler MC, Berry BW (1991). Thyroid-stimulating hormone levels after radiotherapy and combined therapy for head and neck cancer. Head Neck 13 : 420 423.
100. Woo SB, Sonis ST, Monopoli MM et al (1993). A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 72 : 1612 1617.
101. Zorat PL, Paccagnella A, Cavaniglia G et al (2004). Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 96 : 1714 1717.